NCT00062478已完成2 期
Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Objective Tumor Response Rate
研究概览
简要总结
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Karenitecin for intravenous use
干预措施: Karenitecin (BNP1350) (Drug)
结局指标
主要结局
Objective Tumor Response Rate
时间窗: Randomization to end of treatment
次要结局
- Overall Survival(Randomization to date of death due to any cause)
- Overall Safety(Randomization to end of study participation)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Karenitecin (BNP1350) to Treat Malignant MelanomaMelanomaNeoplasmNCT00062491BioNumerik Pharmaceuticals, Inc.46
已完成
2 期
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerRecurrent Ovarian CarcinomaPrimary Peritoneal CarcinomaNCT00054119Gynecologic Oncology Group27
已完成
2 期
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair MutationsGastrointestinal MalignanciesNCT05229588HonorHealth Research Institute8
招募中
2 期
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung CancerNCT05351788Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.110
已完成
2 期
GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial CancerEndometrial CancerNCT01397877ARCAGY/ GINECO GROUP24